DC Chemicals Limited
China
Product Name: ML194
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: CID 2745687
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

264233-05-8

264233-05-8 structure

264233-05-8 structure

Name: CID 2745687
Chemical Name: Methyl 1-(2,4-difluorophenyl)-5-[(E)-{[(2-methyl-2-propanyl)carba mothioyl]hydrazono}methyl]-1H-pyrazole-4-carboxylate
CAS Number: 264233-05-8
Molecular Formula: C₁₇H₁₉F₂N₅O₂S
Molecular Weight: 395.427
Catalog: Research Areas Cardiovascular Disease
Create Date: 2017-01-05 04:23:12
Modify Date: 2024-01-09 16:55:54
CID 2745687 acts as a specific, reversible and competitive GPR35 antagonist with a Ki of 12.8 nM[1].

Name	Methyl 1-(2,4-difluorophenyl)-5-[(E)-{[(2-methyl-2-propanyl)carba mothioyl]hydrazono}methyl]-1H-pyrazole-4-carboxylate
Synonyms	1H-Pyrazole-4-carboxylic acid, 1-(2,4-difluorophenyl)-5-[(E)-[2-[[(1,1-dimethylethyl)amino]thioxomethyl]hydrazinylidene]methyl]-, methyl ester ASTA 3746 Ciclonium bromide Methyl 1-(2,4-difluorophenyl)-5-[(E)-{[(2-methyl-2-propanyl)carbamothioyl]hydrazono}methyl]-1H-pyrazole-4-carboxylate Cicloniumbromid

Description	CID 2745687 acts as a specific, reversible and competitive GPR35 antagonist with a Ki of 12.8 nM[1].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
In Vitro	For ERK1/2 phosphorylation with 1 μM Pamoic acid as the agonist, the CID 2745687 (CID2745687) Ki is 18 nM[1]. CID 2745687 (CID-2745687) is a potent antagonist in β-arrestin-2 interaction assays only at human GPR35[2]. Using the BRET-based GPR35-β-arrestin-2 interaction assay and an EC80 concentration of Zaprinast (20 μM) as agonist, CID 2745687 behaved as a moderately potent, concentration-dependent antagonist at human GPR35 with pIC50=6.70±0.09[2]. CID 2745687 (pIC50=6.27±0.08) fully reverses the agonist action of Cromolyn disodium [2].
In Vivo	CID 2745687 (CID2745687; 1 mg/kg; administrated orally every day for the last 4 weeks), a specific GPR35 antagonist, reverses Lodoxamide-mediated anti-fibrotic effects[3]. Animal Model: Six-week-old male C57BL/6 mice[3] Dosage: 1 mg/kg Administration: Oral administration, every day for 4 weeks Result: Inhibited Lodoxamide-mediated protective effects.
References	[1]. Pingwei Zhao, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8. [2]. Laura Jenkins, et al. Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther. 2012 Dec;343(3):683-95. [3]. Mi-Jeong Kim, et al. Lodoxamide Attenuates Hepatic Fibrosis in Mice: Involvement of GPR35. Biomol Ther (Seoul). 2019 Jun 13;28(1):92-97.

Density	1.3±0.1 g/cm3
Boiling Point	493.6±55.0 °C at 760 mmHg
Molecular Formula	C₁₇H₁₉F₂N₅O₂S
Molecular Weight	395.427
Flash Point	252.3±31.5 °C
Exact Mass	395.122742
PSA	119.67000
LogP	3.05
Vapour Pressure	0.0±1.3 mmHg at 25°C
Index of Refraction	1.591

Hazard Codes	Xi